Announcements Trials

Browse Landscape

Phase

Status

Terminated 3 Active not recruiting 2 Withdrawn 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4 Tumor-Agnostic 1 Other solid neoplasm 1 Myeloid 1

Conditions

Primary Myelofibrosis 1 Myeloproliferative Disorders 1

Interventions

fludarabine phosphate 140 Cyclophosphamide 132 Busulfan 102 Peripheral Blood Stem Cell Transplantation 95 Imatinib Mesylate 94 Mycophenolic Acid 91 Cytarabine 82 Azacitidine 80 Tacrolimus 79 Cyclosporine 78 Whole-Body Irradiation 77 fludarabine 74 Antilymphocyte Serum 71 Methotrexate 65 Filgrastim 63 nilotinib 59 Melphalan 51 Decitabine 49 Radiotherapy 43 Dasatinib 34 Granulocyte Colony-Stimulating Factor 33 ruxolitinib 31 Clofarabine 31 Etoposide 30 thymoglobulin 29 Thiotepa 29 Cord Blood Stem Cell Transplantation 28 sargramostim 27 Methylprednisolone 26 Stem Cell Transplantation 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × fedratinib × Myeloid × Clear all

NCT03952039 2025-08-28

FREEDOM2

Celgene

Phase 3 Completed

202 enrolled 23 charts

Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡